201 related articles for article (PubMed ID: 23582304)
1. A comparative mutational analysis of HIV-1 Vpu subtypes B and C for the identification of determinants required to counteract BST-2/Tetherin and enhance viral egress.
Douglas JL; Bai Y; Gustin JK; Moses AV
Virology; 2013 Jul; 441(2):182-96. PubMed ID: 23582304
[TBL] [Abstract][Full Text] [Related]
2. Separable determinants of subcellular localization and interaction account for the inability of group O HIV-1 Vpu to counteract tetherin.
Vigan R; Neil SJ
J Virol; 2011 Oct; 85(19):9737-48. PubMed ID: 21775465
[TBL] [Abstract][Full Text] [Related]
3. Differential Vpu-Mediated CD4 and Tetherin Downregulation Functions among Major HIV-1 Group M Subtypes.
Umviligihozo G; Cobarrubias KD; Chandrarathna S; Jin SW; Reddy N; Byakwaga H; Muzoora C; Bwana MB; Lee GQ; Hunt PW; Martin JN; Brumme CJ; Bangsberg DR; Karita E; Allen S; Hunter E; Ndung'u T; Brumme ZL; Brockman MA
J Virol; 2020 Jul; 94(14):. PubMed ID: 32376625
[TBL] [Abstract][Full Text] [Related]
4. The C-Terminal End of HIV-1 Vpu Has a Clade-Specific Determinant That Antagonizes BST-2 and Facilitates Virion Release.
Sharma S; Jafari M; Bangar A; William K; Guatelli J; Lewinski MK
J Virol; 2019 Jun; 93(11):. PubMed ID: 30867310
[TBL] [Abstract][Full Text] [Related]
5. The transmembrane domain of HIV-1 Vpu is sufficient to confer anti-tetherin activity to SIVcpz and SIVgor Vpu proteins: cytoplasmic determinants of Vpu function.
Kluge SF; Sauter D; Vogl M; Peeters M; Li Y; Bibollet-Ruche F; Hahn BH; Kirchhoff F
Retrovirology; 2013 Mar; 10():32. PubMed ID: 23514615
[TBL] [Abstract][Full Text] [Related]
6. Functional antagonism of rhesus macaque and chimpanzee BST-2 by HIV-1 Vpu is mediated by cytoplasmic domain interactions.
Yoshida T; Koyanagi Y; Strebel K
J Virol; 2013 Dec; 87(24):13825-36. PubMed ID: 24109238
[TBL] [Abstract][Full Text] [Related]
7. Polarity changes in the transmembrane domain core of HIV-1 Vpu inhibits its anti-tetherin activity.
Lv M; Wang J; Wang X; Zuo T; Zhu Y; Kong W; Yu X
PLoS One; 2011; 6(6):e20890. PubMed ID: 21674066
[TBL] [Abstract][Full Text] [Related]
8. βTrCP is Required for HIV-1 Vpu Modulation of CD4, GaLV Env, and BST-2/Tetherin.
Song YE; Cyburt D; Lucas TM; Gregory DA; Lyddon TD; Johnson MC
Viruses; 2018 Oct; 10(10):. PubMed ID: 30347660
[TBL] [Abstract][Full Text] [Related]
9. Human immunodeficiency virus-1 BF intersubtype recombinant viral protein U second α helix plays an important role in viral release and BST-2 degradation.
De Candia C; Espada C; Duette G; Salomón H; Carobene M
J Gen Virol; 2013 Apr; 94(Pt 4):758-766. PubMed ID: 23223624
[TBL] [Abstract][Full Text] [Related]
10. Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein.
Vigan R; Neil SJ
J Virol; 2010 Dec; 84(24):12958-70. PubMed ID: 20926557
[TBL] [Abstract][Full Text] [Related]
11. Ubiquitination of BST-2 protein by HIV-1 Vpu protein does not require lysine, serine, or threonine residues within the BST-2 cytoplasmic domain.
Gustin JK; Douglas JL; Bai Y; Moses AV
J Biol Chem; 2012 Apr; 287(18):14837-50. PubMed ID: 22383521
[TBL] [Abstract][Full Text] [Related]
12. Lack of adaptation to human tetherin in HIV-1 group O and P.
Yang SJ; Lopez LA; Exline CM; Haworth KG; Cannon PM
Retrovirology; 2011 Sep; 8():78. PubMed ID: 21955466
[TBL] [Abstract][Full Text] [Related]
13. Vpu of a Simian Immunodeficiency Virus Isolated from Greater Spot-Nosed Monkey Antagonizes Human BST-2 via Two AxxxxxxxW Motifs.
Yao W; Yoshida T; Hashimoto S; Takeuchi H; Strebel K; Yamaoka S
J Virol; 2020 Jan; 94(2):. PubMed ID: 31666374
[TBL] [Abstract][Full Text] [Related]
14. The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu.
Rong L; Zhang J; Lu J; Pan Q; Lorgeoux RP; Aloysius C; Guo F; Liu SL; Wainberg MA; Liang C
J Virol; 2009 Aug; 83(15):7536-46. PubMed ID: 19474106
[TBL] [Abstract][Full Text] [Related]
15. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism.
Douglas JL; Viswanathan K; McCarroll MN; Gustin JK; Früh K; Moses AV
J Virol; 2009 Aug; 83(16):7931-47. PubMed ID: 19515779
[TBL] [Abstract][Full Text] [Related]
16. A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction.
Kueck T; Neil SJ
PLoS Pathog; 2012; 8(3):e1002609. PubMed ID: 22479182
[TBL] [Abstract][Full Text] [Related]
17. Efficient Vpu-Mediated Tetherin Antagonism by an HIV-1 Group O Strain.
Mack K; Starz K; Sauter D; Langer S; Bibollet-Ruche F; Learn GH; Stürzel CM; Leoz M; Plantier JC; Geyer M; Hahn BH; Kirchhoff F
J Virol; 2017 Mar; 91(6):. PubMed ID: 28077643
[TBL] [Abstract][Full Text] [Related]
18. Vpu binds directly to tetherin and displaces it from nascent virions.
McNatt MW; Zang T; Bieniasz PD
PLoS Pathog; 2013; 9(4):e1003299. PubMed ID: 23633949
[TBL] [Abstract][Full Text] [Related]
19. Identification of novel key amino acids at the interface of the transmembrane domains of human BST-2 and HIV-1 Vpu.
Pang X; Hu S; Li J; Xu F; Mei S; Zhou J; Cen S; Jin Q; Guo F
Retrovirology; 2013 Aug; 10():84. PubMed ID: 23919512
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 Vpu's lipid raft association is dispensable for counteraction of the particle release restriction imposed by CD317/Tetherin.
Fritz JV; Tibroni N; Keppler OT; Fackler OT
Virology; 2012 Mar; 424(1):33-44. PubMed ID: 22222210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
